Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1

Alectinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor that has sufficient clinical efficacy and satisfactory safety in ALK-positive non-small cell lung cancer (NSCLC) patients with or without brain metastasis. Alectinib has now become an important drug in the first-line treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Hengyi, Lin, Caiyu, Peng, Tao, Hu, Cheng, Lu, Conghua, Li, Li, Wang, Yubo, Han, Rui, Feng, Mingxia, Sun, FenFen, He, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7010683/
https://www.ncbi.nlm.nih.gov/pubmed/32041944
http://dx.doi.org/10.1038/s41419-020-2307-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7010683/
https://www.ncbi.nlm.nih.gov/pubmed/32041944
http://dx.doi.org/10.1038/s41419-020-2307-5

Ejemplares similares